Document is current
Any future updates will be listed below
-
Authors
Rolig, Annah S.
Ziglari, Tahereh
McGee, Grace Helen
Kasiewicz, Melissa J.
Kolbaba, Kenna
Simons, Noah D.
Pucilowska, Joanna
Sfanos, Karen
Redmond, William L.
- License Information
-
More Information
Article History
Received: 25 August 2025
Accepted: 6 February 2026
First Online: 12 February 2026
Declarations
:
: AR, TZ, GM, MK, KK, NS, JP, and KS have no competing interests. WR: Research support from AstraZeneca, Inhibrx, Bristol-Myers Squibb, Shimadzu, and Galecto. Patents/Licensing fees: Galectin Therapeutics. Scientific Advisory Boards: Vesselon, Medicenna, and Veana Therapeutics.
: Preclinical experimental procedures were performed according to the National Institutes of Health Guide for the Care and Use of Laboratory Animals and in accordance with the Earle A. Chiles Research Institute (EACRI) Institutional Animal Care and Use Committee (Animal Welfare Assurance No. A3913–01).
: Not applicable.
